Total Payments
$34,015
2024 Payments
$2,261
Companies
44
Transactions
642
Medicare Patients
24,670
Medicare Billing
$1.5M
Payment Breakdown by Category
Food & Beverage$14,763 (43.4%)
Other$9,120 (26.8%)
Consulting$6,864 (20.2%)
Travel$3,268 (9.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $14,763 | 625 | 43.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,120 | 4 | 26.8% |
| Consulting Fee | $6,864 | 3 | 20.2% |
| Travel and Lodging | $3,268 | 7 | 9.6% |
| Unspecified | $0 | 3 | 0.0% |
Payments by Type
General
$34,015
639 transactions
Ownership
$0
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $10,142 | 26 | $0 (2018) |
| Bard Peripheral Vascular, Inc. | $5,234 | 4 | $0 (2017) |
| Abbott Laboratories | $4,492 | 77 | $0 (2024) |
| Boston Scientific Corporation | $3,099 | 39 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $1,275 | 80 | $0 (2024) |
| Cardiovascular Systems Inc. | $1,218 | 19 | $0 (2019) |
| Medtronic Vascular, Inc. | $1,214 | 55 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $1,171 | 34 | $0 (2024) |
| Philips Electronics North America Corporation | $613.22 | 33 | $0 (2023) |
| PFIZER INC. | $573.19 | 41 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,261 | 87 | Philips North America LLC ($338.78) |
| 2023 | $2,047 | 82 | Abbott Laboratories ($570.01) |
| 2022 | $1,577 | 73 | Abbott Laboratories ($281.85) |
| 2021 | $853.60 | 40 | AstraZeneca Pharmaceuticals LP ($152.61) |
| 2020 | $413.69 | 23 | Medtronic Vascular, Inc. ($155.55) |
| 2019 | $1,687 | 79 | Boston Scientific Corporation ($251.50) |
| 2018 | $7,295 | 101 | Gilead Sciences, Inc. ($4,696) |
| 2017 | $17,881 | 157 | Gilead Sciences Inc ($5,446) |
All Payment Transactions
642 individual payment records from CMS Open Payments — Page 1 of 26
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $4.67 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 12/19/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $21.43 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/17/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $15.86 | General |
| Category: DIABETES | ||||||
| 12/12/2024 | Philips North America LLC | (CM9) Amb Mon & Diag Und (Device) | Food and Beverage | Cash or cash equivalent | $17.81 | General |
| Category: Medical Device | ||||||
| 12/10/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $21.31 | General |
| Category: Genetic Disease | ||||||
| 12/06/2024 | Philips North America LLC | (CM9) Amb Mon & Diag Und (Device) | Food and Beverage | Cash or cash equivalent | $89.18 | General |
| Category: Medical Device | ||||||
| 12/05/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $17.73 | General |
| Category: Obesity | ||||||
| 11/26/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $19.25 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/25/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $12.73 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 10/31/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $15.83 | General |
| Category: Cardiovascular | ||||||
| 10/29/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $20.15 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/29/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $14.90 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/25/2024 | Philips North America LLC | (CM9) Amb Mon & Diag Und (Device) | Food and Beverage | Cash or cash equivalent | $18.28 | General |
| Category: Medical Device | ||||||
| 10/23/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Obesity | ||||||
| 10/18/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $16.39 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 10/16/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $18.20 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/03/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $16.10 | General |
| Category: Obesity | ||||||
| 10/01/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $21.84 | General |
| Category: Heart Failure and Hypertension | ||||||
| 09/30/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $16.12 | General |
| Category: Genetic Disease | ||||||
| 09/23/2024 | Abbott Laboratories | CARDIOMEMS (Device) | Food and Beverage | In-kind items and services | $15.41 | General |
| Category: Heart Failure | ||||||
| 09/19/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $10.56 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 09/11/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $15.66 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 09/03/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $19.06 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/30/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $15.25 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/29/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $28.04 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 32 | 6,082 | 8,267 | $1.6M | $351,034 |
| 2022 | 35 | 5,841 | 8,388 | $1.4M | $347,885 |
| 2021 | 34 | 6,312 | 9,235 | $1.5M | $381,968 |
| 2020 | 34 | 6,435 | 9,794 | $1.5M | $371,019 |
Total Patients
24,670
Total Services
35,684
Medicare Billing
$1.5M
Procedure Codes
141
All Medicare Procedures & Services
141 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 1,228 | 1,995 | $688,335 | $156,966 | 22.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 204 | 232 | $102,488 | $28,373 | 27.7% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 487 | 506 | $181,753 | $26,002 | 14.3% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 401 | 404 | $78,376 | $20,720 | 26.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 190 | 190 | $85,310 | $20,500 | 24.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 145 | 268 | $51,992 | $16,075 | 30.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 118 | 120 | $57,773 | $15,603 | 27.0% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 1,007 | 1,346 | $80,760 | $12,168 | 15.1% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 215 | 216 | $64,019 | $11,858 | 18.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 43 | 70 | $19,530 | $6,289 | 32.2% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Office | 2023 | 266 | 270 | $27,000 | $3,972 | 14.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 291 | 323 | $5,168 | $2,713 | 52.5% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Office | 2023 | 266 | 270 | $20,250 | $2,637 | 13.0% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 235 | 252 | $8,820 | $2,608 | 29.6% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 179 | 193 | $10,615 | $2,519 | 23.7% |
| 93312 | Ultrasound of heart with probe in esophagus, with report | Facility | 2023 | 30 | 30 | $13,860 | $2,434 | 17.6% |
| 93793 | Anticoagulant management of patient taking warfarin | Office | 2023 | 29 | 348 | $11,832 | $2,357 | 19.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 14 | 14 | $8,054 | $2,069 | 25.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 31 | 31 | $9,300 | $2,066 | 22.2% |
| 93228 | Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | Office | 2023 | 132 | 134 | $10,050 | $2,047 | 20.4% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2023 | 14 | 73 | $5,256 | $1,735 | 33.0% |
| 85610 | Blood test, clotting time | Office | 2023 | 34 | 383 | $6,128 | $1,609 | 26.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 192 | 204 | $6,528 | $1,552 | 23.8% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2023 | 71 | 72 | $4,464 | $1,350 | 30.2% |
| 93298 | Evaluation of cardiac rhythm monitor system, remote up to 30 days | Office | 2023 | 14 | 73 | $4,964 | $1,344 | 27.1% |
About Dr. Amit Malhotra, M.D
Dr. Amit Malhotra, M.D is a Cardiovascular Disease healthcare provider based in Southaven, Mississippi. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1699724294.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Amit Malhotra, M.D has received a total of $34,015 in payments from pharmaceutical and medical device companies, with $2,261 received in 2024. These payments were reported across 642 transactions from 44 companies. The most common payment nature is "Food and Beverage" ($14,763).
As a Medicare-enrolled provider, Malhotra has provided services to 24,670 Medicare beneficiaries, totaling 35,684 services with total Medicare billing of $1.5M. Data is available for 4 years (2020–2023), covering 141 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Interventional Cardiology
- Location Southaven, MS
- Active Since 05/09/2006
- Last Updated 06/12/2025
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1699724294
Products in Payments
- Ranexa (Drug) $10,026
- BPV-Lutonix (Device) $5,234
- Omnilink Elite vascular stent system (Device) $2,495
- FFR LINK (Device) $1,800
- Coronary Orbital Atherectomy System (Device) $1,158
- ENTRESTO (Drug) $937.90
- ELIQUIS (Drug) $785.23
- FARXIGA (Drug) $691.86
- (5044) MCOT (Device) $430.17
- BRILINTA (Drug) $403.02
- Repatha (Biological) $363.59
- MITRACLIP (Device) $359.84
- CARDIOMEMS (Device) $339.77
- (CM9) Amb Mon & Diag Und (Device) $338.78
- LEQVIO (Drug) $337.06
- AMVUTTRA (Drug) $284.35
- Claria MRI (Device) $274.63
- VERQUVO (Drug) $268.58
- Resolute (Device) $262.26
- CRT-Ds (Device) $262.22
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.